Evaluation of Low Threshold Buprenorphine Treatment in the Context of COVID-19
COVID-19 背景下低阈值丁丙诺啡治疗的评估
基本信息
- 批准号:10358229
- 负责人:
- 金额:$ 2.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvocateAffectBuprenorphineCOVID-19COVID-19 pandemicCaringCenters of Research ExcellenceClinicClinicalContractsDataDevelopmentEnsureEvaluationEvidence based treatmentGuidelinesHealth PolicyHealthcare SystemsHospitalsIndividualLifeMeasuresMentorsMethodsModelingNatural experimentOutcomeOutpatientsPatient-Focused OutcomesPatientsPharmacologyPoliciesPolicy MakingPopulationPractice GuidelinesPublic HealthResearch PersonnelRhode IslandRiskSafetySavingsSocial DistanceSubstance Use DisorderSystemTimebarrier to carebuprenorphine treatmentcare deliveryevidence baseflexibilityhealth care deliveryimprovedinterestopioid epidemicopioid overdoseopioid use disorderresponsesubstance use treatmentsuccessviral transmission
项目摘要
PROJECT SUMMARY/ABSTRACT
Buprenorphine is an evidence-based pharmacological approach to treating opioid use disorder
(OUD). Despite its efficacy, buprenorphine is significantly underutilized, in part, because of
historically rigid requirements for treatment entry and continuation. To address this concern,
there have been recent calls to establish “low threshold” care to remove barriers to treatment
and improve overall access. The COVID-19 pandemic has placed an unprecedented strain on
the U.S. population and healthcare system. Social distancing measures are now in place to
mitigate the risk of viral transmission. While these public health policies may protect against
contracting COVID-19, they also have the potential to disrupt treatment for substance use
disorders, particularly OUD, which relies heavily on face-to-face healthcare delivery. In
response to such concerns, new guidelines have been released to encourage greater flexibility
in the prescribing of buprenorphine. These changes have the potential to increase access to
and success with buprenorphine treatment for individuals with OUD, however, it remains
unknown how systematic changes related to COVID-19 may affect the practice of
buprenorphine prescribing, treatment utilization, or impact on patient outcomes. The objective of
the present study is to examine, through a mixed-method approach, the preliminary association
of the COVID-19 pandemic with the provision of buprenorphine treatment and patient-level
outcomes across three outpatient buprenorphine clinics affiliated with the largest hospital
system in the state of Rhode Island. Through this Notice of Special Interest (NOSI), the
proposed study will capture and characterize time-sensitive changes that are occurring to
buprenorphine treatment as a result of COVID-19. Information obtained through this study will
identify key factors that may influence implementation of a low threshold approach following the
COVID-19 pandemic. Additionally, this proposal seeks to empirically evaluate a) changes to
buprenorphine prescribing practices and treatment, and b) how changes to the delivery of care
impact patient-level outcomes. Results of this study may be leveraged to inform best-practice
guidelines for buprenorphine prescribing to ensure safety and efficacy of OUD treatment. The
aims outlined within this application align with the overall objectives of COBRE on Opioids and
Overdose to address the opioid crisis by mentoring junior investigators so that they may
transition into independent clinical researchers focused on the development and evaluation of
evidence-based treatment for OUD.
项目总结/摘要
丁丙诺啡是治疗阿片类药物使用障碍的循证药理学方法
(OUD)。尽管其疗效,丁丙诺啡是显着利用不足,部分原因是,
历史上对治疗进入和继续的严格要求。为了解决这个问题,
最近有人呼吁建立“低门槛”护理,以消除治疗障碍,
并改善整体访问。COVID-19大流行给中国带来了前所未有的压力,
美国的人口和医疗体系。社交距离措施现已到位,
降低病毒传播的风险。虽然这些公共卫生政策可以防止
感染COVID-19,它们也有可能破坏物质使用的治疗
疾病,特别是OUD,它严重依赖于面对面的医疗服务。在
为回应这些关注,当局已发布新指引,鼓励市民在这方面有更大的灵活性
丁丙诺啡的处方这些变化有可能增加获得
丁丙诺啡治疗OUD患者的成功,然而,
不知道与COVID-19相关的系统性变化可能如何影响
丁丙诺啡处方、治疗利用或对患者结局的影响。的目标
本研究旨在通过混合方法检验,
提供丁丙诺啡治疗和患者层面的治疗,
隶属于最大医院的三家丁丙诺啡门诊诊所的结果
在罗得岛州的系统。通过这份特别关注通知(NOSI),
拟议的研究将捕捉和描述正在发生的时间敏感性变化,
丁丙诺啡治疗通过本研究获得的信息将
确定可能影响低阈值方法实施的关键因素,
2019冠状病毒病大流行。此外,本建议旨在从经验上评估a)
丁丙诺啡处方实践和治疗,以及B)如何改变护理的提供
影响患者水平的结果。本研究的结果可用于指导最佳实践
丁丙诺啡处方指南,以确保OUD治疗的安全性和有效性。的
本申请中概述的目标与COBRE关于阿片类药物的总体目标一致,
通过指导初级研究人员来解决阿片类药物危机,
转变为独立的临床研究人员,专注于开发和评估
循证治疗OUD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSIAH D RICH其他文献
JOSIAH D RICH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSIAH D RICH', 18)}}的其他基金
Evaluating the decriminalization of non-prescribed buprenorphine in Rhode Island
评估罗德岛州非处方丁丙诺啡的非刑事化
- 批准号:
10676209 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Evaluating the decriminalization of non-prescribed buprenorphine in Rhode Island
评估罗德岛州非处方丁丙诺啡的非刑事化
- 批准号:
10549069 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 2.71万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 2.71万 - 项目类别: